A proteomics signature of NASH

A proteomics signature of NASH

Global prevalence of nonalcoholic fatty liver disease (NAFLD) is presently 30% and increasing. While the majority of afflicted individuals have a relatively non-progressive form, i.e., nonalcoholic fatty liver (NAFL), a significant subset with nonalcoholic steatohepatitis (NASH) are more likely to progress to cirrhosis.

No pharmacological therapies are currently approved for NAFLD or NASH, and liver histology is the reference standard for identification of those at increased risk of progression. Despite the requirement of liver histology improvement as an endpoint for regulatory approval, several factors limit applicability of biopsy in clinical development, including invasiveness and attendant risks, and sampling and observer variability and costs.

As such, there is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.

Recently, longitudinal assessment of over 5,000 serum proteins in 636 individuals with histologically confirmed NAFLD was used to develop and validate models for all four key individual liver biopsy components (steatosis, hepatocellular ballooning, lobular inflammation, fibrosis) and at-risk NASH, and with sufficient sensitivity and precision to characterize drug intervention-related changes. Taken together, these results support continued validation of such proteomics-based models and their promise to enable a “liquid biopsy” assessment of NAFLD.

Learning objectives

  • Needs and applications of non-invasive testing for liver disease
  • Basics of aptamer-based proteomics assessment and compared to standard clinical blood testing
  • Current applications of proteomics biomarkers for unmet needs in NAFLD and NASH

Headshot of Doctor Sanyal

Arun Sanyal, MBBS, MD

Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Interim Chair and Professor, Division of GI, Hepatology & Nutrition
VCU Health System

A proteomics signature of NASH

A presentation by Arun Sanyal, MD, MBBS

Share with colleagues

More webinars

WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure

Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.

Learn more

WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC

In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.

Learn more

WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups

Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or‍ negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched‍ healthy controls.

Learn more

Explore webinars in our interactive viewer